Shinn-Zong Lin

This inventor holds 37 USPTO granted patents and 13 published patent applications, plus 4 CIPO patents and 15 EPO patents, primarily in Stem Cell Therapy. Top assignees: Everfront Biotech Inc., China Medical University, Gwo Xi Stem Cell Applied Technology Co., Ltd.. Active years: 2008-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shinn-Zong Lin. Retrieved from https://idiyas.com/inventor/shinn-zong-lin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 13)

% Patents Active = 83.8

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 15 (Patent Applications = 10)

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 34(Granted Patents)

Location History:

Taipei, TW (2008)
Beitou Chiu, TW (2011)
Hsinchu County, TW (2020)
Zhubei, TW (2016 - 2021)
New Taipei, TW (2016 - 2021)
Hualien, TW (2008 - 2022)
Taichung, TW (2012 - 2024)

Company Filing History:

8 out of 9

Everfront Biotech Inc.

patents

6 out of 110

China Medical University

patents

6 out of 11

Gwo Xi Stem Cell Applied Technology Co., Ltd.

Industrial Technology Research Institute

patents

6. 3 out of 12

National Dong Hwa University

patents

7. 2 out of 3

Buddhist Tzu Chi General Hospital

patents

8. 1 out of 1

Ejia Biotechnology Co., Ltd.

patent

9. 1 out of 1

Hawking Biological Technology Co., Ltd.

Taiwan Mitochondrion Applied Technology

patents

13. 1 out of 9

Taiwan Mitochondrion Applied Technology Co., Ltd.

patents

14. 1 out of 3

Tzu Chi Buddhist General Hospital

patents

where one patent can have more than one assignee

Years Active: 2008-2026

Loading Chart...

Areas of Expertise:

Butylidenephthalide

Stem Cells

Neurodegenerative Diseases

Pharmaceutical Composition

Brain Cancer

Motor Neurons

Hepatic Progenitor Cells

Autophagy Inhibition

Neurotrophic Factors

Cancer Treatment

Pulmonary Fibrosis

Adipose-Derived Stem Cells

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12740964 - Use of phthalide compounds in treatment of meningioma (2026-09-22),

2. 11920157 - Applications of butylidenephthalide (2024-03-05),

3. 11345888 - Method and pharmaceutical composition for continuously maintaining growth of a motor neuron progenitor cell (2022-05-31),

4. 11318170 - Treatment of brain damage using umbilical cord blood cells (2022-05-03),

5. 11020358 - Method for the anti-senescence of and/or rejuvenating stem cells (2021-06-01),

6. 11013716 - Method for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, CXC chemokine receptor 4, and/or immune regulatory factor of stem cell (2021-05-25),

7. 10987339 - Uses of butylidenephthalide (2021-04-27),

8. 10688128 - Use of Z-butylidenephthalide in activating autoimmune system (2020-06-23),

9. 10682335 - Use of butylidenephthalide (Bdph), method of using the same, and method for preparing pharmaceutical composition containing the same (2020-06-16),

10. 10639264 - Mesenchymal stem cell extract and its use (2020-05-05),

11. 10543191 - Use of butylidenephthalide (Bdph), method of using the same, and method for preparing pharmaceutical composition containing the same (2020-01-28),

12. 10493105 - Isolated adipose-derived mesenchymal stem cells treated with angelica extract or butylidenephthalide, and wherein the cells have an increased mitochondrial membrane potential and a decreased level of IL-8, and methods for treating parkinson's disease (2019-12-03),

13. 10463645 - Method for delaying the onset of pulmonary fibrosis or treating pulmonary fibrosis (2019-11-05),

14. 10441566 - Use of butylidenephthalide (2019-10-15),

15. 9889117 - Method for treating and/or delaying the degeneration of Purkinje cells (2018-02-13),

Title: Shinn-Zong Lin: Pioneering Innovations in Healthcare Technology

Introduction:

Shinn-Zong Lin, a visionary inventor based in Taichung, Taiwan, has made significant contributions to the field of healthcare technology. With a rich portfolio of 36 patents, Lin's work revolves around utilizing innovative approaches to enhance medical treatments and promote healthy living.

Latest Patents:

Among Lin's latest patents are groundbreaking inventions focusing on the applications of butylidenephthalide (BP) and methods for maintaining the growth of motor neuron progenitor cells. These patents showcase his commitment to advancing stem cell research, promoting adipose cell differentiation, and developing pharmaceutical compositions for treating motor neuron-related disorders.

Career Highlights:

Having worked at prestigious companies such as Everfront Biotech Inc. and China Medical University, Lin has established himself as a key figure in bridging the gap between academia and industry. His dedication to translating cutting-edge research into practical solutions has led to the development of novel medical interventions with the potential to revolutionize healthcare practices globally.

Collaborations:

Throughout his career, Lin has collaborated with esteemed colleagues, including Horng-Jyh Harn and Tzyy-Wen Chiou. Together, they have synergized their expertise to drive innovation in the field of regenerative medicine, neurology, and biotechnology. These collaborations have yielded fruitful results, paving the way for the development of transformative medical technologies.

Conclusion:

In conclusion, Shinn-Zong Lin's relentless pursuit of innovation in healthcare technology has positioned him as a trailblazer in the realm of inventions. His patents not only reflect his technical prowess but also underscore his unwavering commitment to improving patient outcomes and advancing the frontiers of medical science. Lin's legacy serves as an inspiration to aspiring inventors and researchers, propelling the industry towards a future defined by cutting-edge discoveries and transformative breakthroughs.

Profile summary based on public USPTO records.